{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:31:28Z","timestamp":1781512288244,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current guidelines recommend routine lymph node dissection (LND) for intrahepatic cholangiocarcinoma (iCCA) to achieve adequate staging; however, real-world compliance remains suboptimal. This study evaluated whether, compared with routine approaches, selective lymphadenectomy, on the basis of clinical judgment, compromises oncological outcomes in patients with iCCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis of 179 patients who underwent curative hepatectomy for iCCA between 2014 and 2024 was performed. The cohort included pure cholangiocarcinoma (CCA,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009102) and combined hepatocellular-cholangiocarcinoma (HCC-CCA,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200977) patients. Patients were categorized by pathological nodal status: pN0 (LND performed, negative nodes), pN1 (LND performed, positive nodes), and pNx (no LND performed). Logistic regression identified factors influencing LND decisions. Survival outcomes were analyzed via the Kaplan\u2012Meier method and Cox proportional hazards modeling. Subgroup analysis was performed to explore the outcomes in CCA and HCC-CCA separately.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LND was performed in 54 patients (30%), with significant variation based on tumor characteristics. Preoperative cholangiocarcinoma diagnosis was the primary factor influencing LND decisions (OR 3.33, 95% CI 1.54\u20137.34;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). The median overall survival (OS) was 30.5, 17.4, and 59.1 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), and median progression-free survival (PFS) was 21.2, 8.4, and 16.6 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042) for pN0, pN1, and pNx, respectively. Subgroup analysis for CCA and HCC-CCA separately showed a similar Kaplan-Meier curve pattern, but the differences were not statistically significant because of the uneven distribution between groups. After adjusting for age, tumor stage, and histology, no significant difference in survival was detected between the pNx and pN0 groups (HR 0.78, 95% CI 0.46\u20131.30;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.34). Patients with pure CCA had worse survival than those with HCC-CCA (HR 1.68, 95% CI 1.03\u20132.75;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040). Adequate lymphadenectomy (\u2265\u20096 nodes) was achieved in only 26% of patients who underwent LND.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the low compliance with the guidelines regarding lymph node dissection for intrahepatic cholangiocarcinoma in real-world settings. However, compared to lymphadenectomy with negative nodes, selective lymph node dissection based on clinical suspicion does not compromise the overall survival. These findings support individualized surgical approaches rather than universal lymphadenectomy protocols and challenge current guidelines mandating routine LND for all iCCA patients. Future guidelines should incorporate risk-stratified decision-making in lymph node management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-04034-3","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:46:37Z","timestamp":1761043597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Selective lymph node dissection in intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma may not impair oncological outcomes: a single-center retrospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Wei-Hsun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-8066","authenticated-orcid":false,"given":"Ting-Kai","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Min","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Jui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Jui","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Jyh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Shen","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"1","key":"4034_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104\u201314. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.013.","journal-title":"J Hepatol"},{"key":"4034_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jamcollsurg.2008.04.031","volume":"207","author":"CW Hammill","year":"2008","unstructured":"Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 2008;207:594\u2013603. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2008.04.031.","journal-title":"J Am Coll Surg"},{"key":"4034_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39:19\u201331. https:\/\/doi.org\/10.1111\/liv.14095.","journal-title":"Liver Int"},{"key":"4034_CR4","first-page":"1159","volume":"11","author":"HR Shin","year":"2010","unstructured":"Shin HR, Oh JK, Masuyer E, et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma - focus on East and South-Eastern Asia. Asian Pac J Cancer Prev. 2010;11:1159\u201366.","journal-title":"Asian Pac J Cancer Prev"},{"key":"4034_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Kostakis ID, Machairas N, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:25\u201355. https:\/\/doi.org\/10.3322\/caac.21759.","journal-title":"CA Cancer J Clin"},{"key":"4034_CR6","doi-asserted-by":"publisher","first-page":"19084","DOI":"10.1038\/s41598-024-70124-z","volume":"14","author":"YJ Chang","year":"2024","unstructured":"Chang YJ, Chang YJ, Chen LJ. Prognostic factors in patients with intrahepatic cholangiocarcinoma. Sci Rep. 2024;14:19084. https:\/\/doi.org\/10.1038\/s41598-024-70124-z.","journal-title":"Sci Rep"},{"key":"4034_CR7","doi-asserted-by":"publisher","first-page":"14744","DOI":"10.18632\/oncotarget.4539","volume":"6","author":"G Brandi","year":"2015","unstructured":"Brandi G, Farioli A, Astolfi A, et al. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6:14744\u201353. https:\/\/doi.org\/10.18632\/oncotarget.4539.","journal-title":"Oncotarget"},{"key":"4034_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJ, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"4034_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/lt.24711","volume":"23","author":"DH Jung","year":"2017","unstructured":"Jung DH, Hwang S, Song GW, et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection. Liver Transpl. 2017;23(3):330\u201341. https:\/\/doi.org\/10.1002\/lt.24711.","journal-title":"Liver Transpl"},{"key":"4034_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.humpath.2019.11.001","volume":"96","author":"A Sciarra","year":"2020","unstructured":"Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2020;96:48\u201355. https:\/\/doi.org\/10.1016\/j.humpath.2019.11.001.","journal-title":"Hum Pathol"},{"key":"4034_CR11","doi-asserted-by":"publisher","first-page":"e1430","DOI":"10.1002\/onco.13893","volume":"26","author":"PD Chen","year":"2021","unstructured":"Chen PD, Chen LJ, Chang YJ, et al. Long-Term survival of combined Hepatocellular-Cholangiocarcinoma: A nationwide study. Oncologist. 2021;26:e1430\u201340. https:\/\/doi.org\/10.1002\/onco.13893.","journal-title":"Oncologist"},{"key":"4034_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hep.29789","volume":"68","author":"E Brunt","year":"2018","unstructured":"Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68:113\u201326. https:\/\/doi.org\/10.1002\/hep.29789.","journal-title":"Hepatology"},{"key":"4034_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.10.506","volume":"33","author":"A Vogel","year":"2022","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:466\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.506.","journal-title":"Ann Oncol"},{"key":"4034_CR14","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.esmoop.2024.103647","volume":"9","author":"LT Chen","year":"2024","unstructured":"Chen LT, Vogel A, Chen MH, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. ESMO Open. 2024;9:103647. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103647.","journal-title":"ESMO Open"},{"key":"4034_CR15","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers, Version 2.2025. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2025 [cited 2025 Sep 25]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1517."},{"key":"4034_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/jso.25825","volume":"121","author":"K Sahara","year":"2020","unstructured":"Sahara K, Tsilimigras DI, Maithel SK, et al. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: an analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol. 2020;121:477\u201384. https:\/\/doi.org\/10.1002\/jso.25825.","journal-title":"J Surg Oncol"},{"key":"4034_CR17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.021.","journal-title":"J Hepatol"},{"key":"4034_CR18","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43:1777\u201387. https:\/\/doi.org\/10.1007\/s00268-019-04966-4.","journal-title":"World J Surg"},{"key":"4034_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s11605-017-3652-2","volume":"22","author":"XF Zhang","year":"2018","unstructured":"Zhang XF, Chen Q, Kimbrough CW, et al. Lymphadenectomy for intrahepatic cholangiocarcinoma: has nodal evaluation been increasingly adopted by surgeons over time? A national database analysis. J Gastrointest Surg. 2018;22:668\u201375. https:\/\/doi.org\/10.1007\/s11605-017-3652-2.","journal-title":"J Gastrointest Surg"},{"key":"4034_CR20","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"key":"4034_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol"},{"key":"4034_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15:527\u201336. https:\/\/doi.org\/10.1080\/17474124.2021.1853527.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4034_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jhbp.211","volume":"22","author":"M Miyazaki","year":"2015","unstructured":"Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese society of Hepato-biliary-pancreatic surgery: 3(rd) english edition. J Hepatobiliary Pancreat Sci. 2015;22:181\u201396. https:\/\/doi.org\/10.1002\/jhbp.211.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"4034_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00423-024-03564-w","volume":"410","author":"J Yoshino","year":"2025","unstructured":"Yoshino J, Nara S, Yokoyama M, et al. Prognostic impact of lymph node dissection in intrahepatic cholangiocarcinoma: a propensity score analysis. Langenbecks Arch Surg. 2025;410:3. https:\/\/doi.org\/10.1007\/s00423-024-03564-w.","journal-title":"Langenbecks Arch Surg"},{"key":"4034_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jhbp.1038","volume":"29","author":"Y Umeda","year":"2022","unstructured":"Umeda Y, Mitsuhashi T, Kojima T, et al. Impact of lymph node dissection on clinical outcomes of intrahepatic cholangiocarcinoma: inverse probability of treatment weighting with survival analysis. J Hepatobiliary Pancreat Sci. 2022;29:217\u201329. https:\/\/doi.org\/10.1002\/jhbp.1038.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"4034_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jhep.2022.10.021","volume":"78","author":"C Sposito","year":"2023","unstructured":"Sposito C, Ratti F, Cucchetti A, et al. Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma. J Hepatol. 2023;78:356\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.021.","journal-title":"J Hepatol"},{"key":"4034_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.surg.2021.12.026","volume":"171","author":"SH Kim","year":"2022","unstructured":"Kim SH, Han DH, Choi GH, et al. Prognostic impact of the metastatic lymph node number in intrahepatic cholangiocarcinoma. Surgery. 2022;171:1373\u20138. https:\/\/doi.org\/10.1016\/j.surg.2021.12.026.","journal-title":"Surgery"},{"key":"4034_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12893-021-01363-4","volume":"21","author":"H Hu","year":"2021","unstructured":"Hu H, Xu G, Du S, et al. The role of lymph node dissection in intrahepatic cholangiocarcinoma: a multicenter retrospective study. BMC Surg. 2021;21:359. https:\/\/doi.org\/10.1186\/s12893-021-01363-4.","journal-title":"BMC Surg"},{"key":"4034_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11605-018-3899-2","volume":"23","author":"SH Kim","year":"2019","unstructured":"Kim SH, Han DH, Choi GH, et al. Oncologic impact of lymph node dissection for intrahepatic cholangiocarcinoma: a propensity score-matched study. J Gastrointest Surg. 2019;23:538\u201344. https:\/\/doi.org\/10.1007\/s11605-018-3899-2.","journal-title":"J Gastrointest Surg"},{"key":"4034_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.surg.2019.06.025","volume":"166","author":"T Yoh","year":"2019","unstructured":"Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: a multicenter study. Surgery. 2019;166:975\u201382. https:\/\/doi.org\/10.1016\/j.surg.2019.06.025.","journal-title":"Surgery"},{"key":"4034_CR31","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1245\/s10434-009-0631-1","volume":"16","author":"SB Choi","year":"2009","unstructured":"Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009;16:3048\u201356. https:\/\/doi.org\/10.1245\/s10434-009-0631-1.","journal-title":"Ann Surg Oncol"},{"key":"4034_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.hpb.2020.01.009","volume":"22","author":"JG Navarro","year":"2020","unstructured":"Navarro JG, Lee JH, Kang I, et al. Prognostic significance of and risk prediction model for lymph node metastasis in resectable intrahepatic cholangiocarcinoma: do all require lymph node dissection? HPB. 2020;22:939\u201347. https:\/\/doi.org\/10.1016\/j.hpb.2020.01.009.","journal-title":"HPB"},{"key":"4034_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gassur.2023.10.002","volume":"28","author":"K Sahara","year":"2024","unstructured":"Sahara K, Tsilimigras DI, Moro A, et al. Predicting lymph node metastasis in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2024;28:109\u201317. https:\/\/doi.org\/10.1016\/j.gassur.2023.10.002.","journal-title":"J Gastrointest Surg"},{"key":"4034_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.957792","volume":"12","author":"F Li","year":"2022","unstructured":"Li F, Jiang Y, Jiang L, et al. Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Front Oncol. 2022;12:957792. https:\/\/doi.org\/10.3389\/fonc.2022.957792.","journal-title":"Front Oncol"},{"key":"4034_CR35","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149:565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137.","journal-title":"JAMA Surg"},{"key":"4034_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.hpb.2023.11.007","volume":"26","author":"M Yeow","year":"2024","unstructured":"Yeow M, Fong KY, Zhao JJ, et al. Value of lymph node dissection in intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. HPB. 2024;26:161\u201370. https:\/\/doi.org\/10.1016\/j.hpb.2023.11.007.","journal-title":"HPB"},{"key":"4034_CR37","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.hpb.2018.12.011","volume":"21","author":"R Zhou","year":"2019","unstructured":"Zhou R, Lu D, Li W, et al. Is lymph node dissection necessary for resectable intrahepatic cholangiocarcinoma? A systematic review and meta-analysis. HPB. 2019;21:784\u201392. https:\/\/doi.org\/10.1016\/j.hpb.2018.12.011.","journal-title":"HPB"},{"issue":"11","key":"4034_CR38","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.4251\/wjgo.v15.i11.2017","volume":"15","author":"M Atif","year":"2023","unstructured":"Atif M, Borakati A, Mavroeidis VK. Role of routine lymph node dissection alongside resection of intrahepatic cholangiocarcinoma: systematic review and meta-analysis. World J Gastrointest Oncol. 2023;15(11):2017\u201332. https:\/\/doi.org\/10.4251\/wjgo.v15.i11.2017.","journal-title":"World J Gastrointest Oncol"},{"key":"4034_CR39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ejso.2019.04.019","volume":"45","author":"G Lurje","year":"2019","unstructured":"Lurje G, Bednarsch J, Czigany Z, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2019;45:1468\u201378. https:\/\/doi.org\/10.1016\/j.ejso.2019.04.019.","journal-title":"Eur J Surg Oncol"},{"key":"4034_CR40","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00464-015-4430-4","volume":"30","author":"F Ratti","year":"2016","unstructured":"Ratti F, Cipriani F, Ariotti R, et al. Safety and feasibility of laparoscopic liver resection with associated lymphadenectomy for intrahepatic cholangiocarcinoma: a propensity score-based case-matched analysis from a single institution. Surg Endosc. 2016;30:1999\u20132010. https:\/\/doi.org\/10.1007\/s00464-015-4430-4.","journal-title":"Surg Endosc"},{"key":"4034_CR41","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jhep.2022.07.029","volume":"81","author":"BJ Pepe-Mooney","year":"2024","unstructured":"Pepe-Mooney BJ, Dill MT, Alemany A, et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J Hepatol. 2024;81:1005\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.029.","journal-title":"J Hepatol"},{"key":"4034_CR42","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1038\/s41598-021-91823-x","volume":"11","author":"L Yin","year":"2021","unstructured":"Yin L, Zhao S, Zhu H, et al. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. Sci Rep. 2021;11:11823. https:\/\/doi.org\/10.1038\/s41598-021-91823-x.","journal-title":"Sci Rep"},{"issue":"11","key":"4034_CR43","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s11605-017-3499-6","volume":"21","author":"XF Zhang","year":"2017","unstructured":"Zhang XF, Bagante F, Chakedis J, et al. Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy. J Gastrointest Surg. 2017;21(11):1841\u201350. https:\/\/doi.org\/10.1007\/s11605-017-3499-6.","journal-title":"J Gastrointest Surg"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04034-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:46:40Z","timestamp":1761043600000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04034-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4034"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04034-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7003491\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Approval was granted by the Institutional Review Board of National Cheng Kung University Hospital (No. A-ER-110\u2013059). Given the retrospective nature of this study and the use of de-identified patient data, the Institutional Review Board waived the requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}